{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:24:45Z","timestamp":1786119885612,"version":"build-2736575974"},"reference-count":131,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/wnf.0b013e318215c2f7","type":"journal-article","created":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T09:29:01Z","timestamp":1305624541000},"page":"111-126","source":"Crossref","is-referenced-by-count":28,"title":["Neurobiological Background for the Development of New Drugs in Schizophrenia"],"prefix":"10.1097","volume":"34","author":[{"given":"Francisco","family":"L\u00f3pez-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilio","family":"\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/070674379704200205","article-title":"The history of the psychopharmacology of schizophrenia.","volume":"42","author":"Lehmann","year":"1997","journal-title":"Can J Psychiatry"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0278-5846(01)00160-9","article-title":"Pharmacotherapy of mental illness. A historical analysis.","volume":"25","author":"Ban","year":"2001","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatr"},{"key":"R4-5-20210203","first-page":"305","article-title":"Propierties pharmacodynamiques du chlorhydrate de chloro-3 (dimethypamine 3propyl)-10 phenotiazine (4560RP).","volume":"92","author":"Courvoisier","year":"1953","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0278-5846(03)00165-9","article-title":"Half a century since the clinical introduction of chlorpromazine and the birth of modern psychopharmacology.","volume":"28","author":"Lopez-Munoz","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10401230591002002","article-title":"History of the discovery and clinical introduction of chlorpromazine.","volume":"17","author":"Lopez-Munoz","year":"2005","journal-title":"Ann Clin Psychiatry"},{"key":"R7-5-20210203","first-page":"337","article-title":"Etude et experimentations cliniques du R 1625 ou haloperidol, nouveau neuroleptique et \"neurodysleptique\".","volume":"59","author":"Divry","year":"1959","journal-title":"Acta Neurol Psychiatr Belg"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.brainresbull.2009.01.005","article-title":"The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.","volume":"79","author":"Lopez-Munoz","year":"2009","journal-title":"Brain Res Bull"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/14728214.13.3.479","article-title":"Emerging drugs for schizophrenia.","volume":"13","author":"Agid","year":"2008","journal-title":"Exp Opin Emerg Drugs"},{"issue":"suppl 12","key":"R11-5-20210203","first-page":"22","article-title":"A historical perspective of clozapine.","volume":"60","author":"Hippius","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1552-4604.1997.tb04314.x","article-title":"New dimensions in the pharmacologic treatment of the schizophrenia and related psychoses.","volume":"37","author":"Bucley","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/YCO.0b013e328329cd73","article-title":"Antipsychotics in the early stage of development.","volume":"22","author":"Biedermann","year":"2009","journal-title":"Curr Opin Psychiatr"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action.","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/00023210-200418130-00007","article-title":"Amisulpride. A review of its use in the management of schizophrenia.","volume":"18","author":"McKeage","year":"2004","journal-title":"CNS Drugs"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview.","volume":"172","author":"Gardner","year":"2005","journal-title":"Can Med Assoc J"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy based analysis of the contributions of various receptors to antipsychotics induced weight gain and diabetes mellitus.","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nurt.2008.10.020","article-title":"Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.","volume":"6","author":"Kim","year":"2009","journal-title":"Neurotherapeutics"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain.","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacol Toxicol"},{"key":"R24-5-20210203","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.","volume":"160","author":"Van Rossum","year":"1966","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"suppl 22","key":"R25-5-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1192\/S000712500029257X","article-title":"Dopamine receptors and antipsychotic drug response.","volume":"163","author":"Sunahara","year":"1993","journal-title":"Br J Psychiatry"},{"key":"R26-5-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00001504-199401000-00017","article-title":"Drug treatment of schizophrenia: myths and realities.","volume":"7","author":"Gerlach","year":"1994","journal-title":"Curr Opin Psychiatry"},{"key":"R27-5-20210203","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1126\/science.2878495","article-title":"Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.","volume":"234","author":"Wong","year":"1986","journal-title":"Science"},{"key":"R28-5-20210203","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal effects.","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R29-5-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mp.4000336","article-title":"Antipsychotic drugs which elicit little or no parkinsonism blind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.","volume":"3","author":"Seeman","year":"1998","journal-title":"Mol Psychiatry"},{"key":"R30-5-20210203","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.","volume":"25","author":"Kapur","year":"2000","journal-title":"J Psychiatry Neurosci"},{"key":"R31-5-20210203","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis.","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R32-5-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1358\/dot.2007.43.4.1067342","article-title":"Extended-release paliperidone: efficacy, safety and tolerability of a new atypical antipsychotic.","volume":"43","author":"Owen","year":"2007","journal-title":"Drugs Today"},{"key":"R33-5-20210203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists. A new class of antipsychotics.","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"R34-5-20210203","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","article-title":"Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.","volume":"200","author":"Casey","year":"2008","journal-title":"Psychopharmacology"},{"key":"R36-5-20210203","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1586\/ern.09.119","article-title":"Iloperidone: a new option for the treatment of schizophrenia.","volume":"9","author":"Cutler","year":"2009","journal-title":"Exp Rev Neurother"},{"key":"R37-5-20210203","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"issue":"suppl 380","key":"R38-5-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0447.1994.tb05831.x","article-title":"Preclinical findings with new antipsychotic agents: what makes them atypical?","volume":"89","author":"Jackson","year":"1994","journal-title":"Acta Psychiatr Scand"},{"key":"R39-5-20210203","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0773.1995.tb00154.x","article-title":"Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents?","volume":"76","author":"Hacksell","year":"1995","journal-title":"Pharmacol Toxicol"},{"key":"R40-5-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-199708010-00001","article-title":"Dopamine D4 receptors, potential therapeutic implications in the treatment of schizophrenia.","volume":"8","author":"Shaikh","year":"1997","journal-title":"CNS Drugs"},{"key":"R41-5-20210203","first-page":"224","article-title":"Localization and function of the D-3 dopamine receptor.","volume":"42","author":"Sokoloff","year":"1992","journal-title":"Arzneimittel Forsch Drug Res"},{"key":"R42-5-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0893-133X(95)00068-O","article-title":"New insights into the biology of schizophrenia through the mechanism of action of clozapine.","volume":"13","author":"Brunello","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"suppl","key":"R44-5-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0924-977X(95)00022-H","article-title":"Dopamine agonists in schizophrenia: a review.","volume":"5","author":"Benkert","year":"1995","journal-title":"Eur Neuropsychopharmacol"},{"key":"R45-5-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0924-977X(96)00393-8","article-title":"Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy.","volume":"7","author":"Kasper","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"R46-5-20210203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0306-3623(88)90005-5","article-title":"Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology.","volume":"19","author":"Waddington","year":"1988","journal-title":"Gen Pharmacol"},{"key":"R47-5-20210203","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.mp.4000281","article-title":"Possible role of dopamine D1 receptors in schizophrenia.","volume":"2","author":"Okubo","year":"1997","journal-title":"Mol Psychiatry"},{"key":"R48-5-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2007.03.011","article-title":"A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.","volume":"93","author":"George","year":"2007","journal-title":"Schizophr Res"},{"key":"R49-5-20210203","first-page":"390","article-title":"The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotics drugs.","volume":"25","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"R50-5-20210203","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2165\/0003495-200868160-00002","article-title":"Upcoming agents for the treatment of schizophrenia. Mechanism of action, efficacy and tolerability.","volume":"16","author":"Bishara","year":"2008","journal-title":"Drugs"},{"key":"R51-5-20210203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0079-6123(08)00906-0","article-title":"Alterations of dopamine and serotonin transmission in schizophrenia.","volume":"172","author":"Remington","year":"2008","journal-title":"Prog Brain Res"},{"issue":"suppl 25","key":"R52-5-20210203","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000293173","article-title":"Towards more effective antipsychotic treatment.","volume":"165","author":"Kane","year":"1994","journal-title":"Br J Psychiatr"},{"key":"R53-5-20210203","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00004714-199502001-00002","article-title":"The evolution of the serotonin-dopamine antagonist concept.","volume":"15","author":"Huttunen","year":"1995","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 388","key":"R54-5-20210203","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0447.1995.tb05941.x","article-title":"New drugs for the treatment of schizophrenic patients.","volume":"91","author":"Fleischhacker","year":"1995","journal-title":"Acta Psychiatr Scand"},{"key":"R55-5-20210203","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.107.121715","article-title":"ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.","volume":"322","author":"Gardell","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R56-5-20210203","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656560802532707","article-title":"Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.","volume":"9","author":"Abbas","year":"2008","journal-title":"Exp Opin Pharmacother"},{"key":"R57-5-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1176\/ajp.156.3.419","article-title":"Placebo-controlled study of the D4\/5-HT2A antagonist fananserin in the treatment of schizophrenia.","volume":"156","author":"Truffinet","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"suppl 4","key":"R58-5-20210203","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.1016\/S0924-977X(07)70740-X","article-title":"Vabicaserin: effects of a novel 5HT2C agonist on medial prefrontal cortex neurotransmission, cognition and sensorimotor gating.","volume":"17","author":"Rosenzweig-Lipson","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"R59-5-20210203","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.clpt.6100049","article-title":"Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.","volume":"81","author":"Lim","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R60-5-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R61-5-20210203","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.","volume":"63","author":"Citrome","year":"2009","journal-title":"Int J Clin Pract"},{"key":"R62-5-20210203","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R63-5-20210203","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0014-2999(88)90528-6","article-title":"Activation of a 5-HT2 receptor releases dopamine from rat striatal slices.","volume":"155","author":"Blandina","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"R64-5-20210203","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","article-title":"Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.","volume":"268","author":"Roth","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R65-5-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-007-0934-5","article-title":"Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.","volume":"196","author":"Loiseau","year":"2008","journal-title":"Psychopharmacology"},{"key":"R66-5-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","article-title":"Interactions between glutamatergic and monoaminergic systems within the basal ganglia implications for schizophrenia and Parkinson's disease.","volume":"13","author":"Carlsson","year":"1990","journal-title":"Trends Neurosci"},{"key":"R67-5-20210203","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.bmcl.2007.01.093","article-title":"M4 agonists\/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds.","volume":"17","author":"Suckling","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"R68-5-20210203","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0091-3057(01)00744-4","article-title":"Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.","volume":"71","author":"Pouzet","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"R69-5-20210203","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1021\/jm050148z","article-title":"Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-omega-(1H-indol-3-yl)alkylpiperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.","volume":"48","author":"Smid","year":"2005","journal-title":"J Med Chem"},{"key":"R70-5-20210203","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0022-3565(25)11335-9","article-title":"Antagonism by antimuscarinic and reuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells.","volume":"260","author":"Bolden","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"R71-5-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/026988119400800401","article-title":"Putting the \"A\" in atypical: does -2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?","volume":"8","author":"Nutt","year":"1994","journal-title":"J Psychopharmacol"},{"key":"R72-5-20210203","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia.","volume":"7","author":"Dean","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R73-5-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2003.09.010","article-title":"What's atypical about atypical antipsychotic drugs?","volume":"4","author":"Meltzer","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"R74-5-20210203","first-page":"81","article-title":"El futuro de la farmacoterapia en la esquizofrenia.","volume":"1","author":"Kane","year":"2003","journal-title":"World Psychiatry (Ed Esp)"},{"key":"R75-5-20210203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2006.08.010","article-title":"Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors.","volume":"73","author":"Hogg","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"R76-5-20210203","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R77-5-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1440-0979.2003.00278.x","article-title":"The association between schizophrenia and cigarette smoking; a review of the literature and implications for mental health nursing practice.","volume":"12","author":"McCloughen","year":"2003","journal-title":"Int J Ment Health Nur"},{"key":"R78-5-20210203","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-003-1750-1","article-title":"Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.","volume":"174","author":"Martin","year":"2004","journal-title":"Psychopharmacology"},{"key":"R79-5-20210203","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia.","volume":"165","author":"Freedman","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R80-5-20210203","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00213-006-0675-x","article-title":"Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.","volume":"191","author":"Dunbar","year":"2007","journal-title":"Psychopharmacology"},{"key":"R81-5-20210203","first-page":"281","article-title":"The pharmacology of olanzapine and other new antipsychotic agents.","volume":"2","author":"Moore","year":"1993","journal-title":"Curr Opin Invest Drugs"},{"key":"R82-5-20210203","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0140-6736(90)91237-5","article-title":"Effect of famotidine on deficit symptoms of schizophrenia.","volume":"335","author":"Kaminsky","year":"1990","journal-title":"Lancet"},{"key":"R83-5-20210203","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2165\/00023210-199708040-00002","article-title":"Histamine H2 receptor antagonists in schizophrenia, rationale for use and therapeutic potential.","volume":"8","author":"Deutsch","year":"1997","journal-title":"CNS Drugs"},{"key":"R84-5-20210203","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","article-title":"Schwartz BF2.649 1-{3-3-(4-chlorophenyl)propoxypropyl}piperidine, hydrochloride, a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology.","volume":"320","author":"Ligneau","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R85-5-20210203","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/jpet.107.120311","article-title":"GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.","volume":"321","author":"Medhurst","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R86-5-20210203","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis.","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol Neurobiol"},{"key":"R87-5-20210203","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0304-3940(80)90178-0","article-title":"Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.","volume":"20","author":"Kim","year":"1980","journal-title":"Neurosci Lett"},{"key":"R88-5-20210203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.brainresrev.2007.09.006","article-title":"The role of cortical inhibition in the pathophysiology and treatment of schizophrenia.","volume":"56","author":"Daskalakis","year":"2007","journal-title":"Brain Res Rev"},{"key":"R89-5-20210203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/pr.107.00107","article-title":"Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.","volume":"60","author":"Lieberman","year":"2008","journal-title":"Pharmacol Rev"},{"key":"R90-5-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/00048679709073795","article-title":"Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia.","volume":"31","author":"Catts","year":"1997","journal-title":"Aust N Z J Psychiatry"},{"key":"R91-5-20210203","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0006-3223(89)90072-3","article-title":"Excitatory amino acids and neuropsychiatric disorders.","volume":"26","author":"Olney","year":"1989","journal-title":"Biol Psychiatry"},{"key":"R92-5-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02439594","article-title":"The effects of some polyamines on putative behavioural indices of mesolimbic versus striatal dopaminergic function.","volume":"93","author":"Hirsch","year":"1987","journal-title":"Psychopharmacology"},{"key":"R93-5-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00023210-199707010-00006","article-title":"The glutamate hypothesis of schizophrenia, therapeutic implications.","volume":"7","author":"Ishimaru","year":"1997","journal-title":"CNS Drugs"},{"key":"R94-5-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0022-3565(25)24934-5","article-title":"Metaphit, a proposed phencyclidine receptor acylator: phencylidine like behavioral effects and evidence of absence of antagonist activity in pigeons, and in rhesus monkeys.","volume":"237","author":"Koeck","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"R95-5-20210203","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1126\/science.2841759","article-title":"Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes.","volume":"241","author":"Kleckner","year":"1988","journal-title":"Science"},{"key":"R96-5-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-2999(95)00375-U","article-title":"DL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles.","volume":"284","author":"Kehne","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"R97-5-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0278-5846(91)90079-G","article-title":"Glutamate and glycine co-activate while polyamines merely modulate the NMDA receptor complex.","volume":"15","author":"Lehman","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R98-5-20210203","first-page":"16","article-title":"Latest trends in schizophrenia.","volume":"13-","author":"Cheung","year":"1998","journal-title":"Pharmaprojects Magazine"},{"key":"R99-5-20210203","first-page":"468","article-title":"Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.","volume":"12","author":"Javitt","year":"2009","journal-title":"Curr Opin Drug Disc Dev"},{"key":"R100-5-20210203","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/092986706776360932","article-title":"Glycine transporter type-1 and its inhibitors.","volume":"13","author":"Harsing","year":"2006","journal-title":"Curr Med Chem"},{"key":"R101-5-20210203","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0091-3057(02)01078-X","article-title":"The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study.","volume":"74","author":"Harsing","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"R102-5-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2007.04.038","article-title":"Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.","volume":"63","author":"Lane","year":"2008","journal-title":"Biol Psychiatry"},{"key":"R103-5-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1527-3458.2002.tb00228.x","article-title":"LY404187: a novel positive allosteric modulator of AMPA receptors.","volume":"8","author":"Quirk","year":"2002","journal-title":"CNS Drug Rev"},{"key":"R104-5-20210203","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1517\/13543776.10.10.1539","article-title":"Positive modulators of the AMPA receptor.","volume":"10","author":"Grove","year":"2000","journal-title":"Exp Opin Ther Pat"},{"key":"R105-5-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00004714-200110000-00005","article-title":"A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.","volume":"21","author":"Goff","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R106-5-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.npp.1301444","article-title":"A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia.","volume":"33","author":"Goff","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R107-5-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"R108-5-20210203","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s00018-009-0130-3","article-title":"Group II metabotropic glutamate receptors and schizophrenia.","volume":"66","author":"Moreno","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"R109-5-20210203","first-page":"1112","article-title":"Glutamate receptor ligands as anxiolytics.","volume":"2","author":"Chojnacka-Wojcik","year":"2001","journal-title":"Curr Opin Invest Drugs"},{"key":"R110-5-20210203","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial.","volume":"13","author":"Patil","year":"2007","journal-title":"Nat Med"},{"key":"R111-5-20210203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0014-2999(90)90260-D","article-title":"Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D2 receptors.","volume":"117","author":"Bowen","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"R112-5-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/npp.1994.5","article-title":"BMY 14802, a sigma receptor ligand for the treatment of schizophrenia.","volume":"10","author":"Gewirtz","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"R113-5-20210203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00023210-200418050-00001","article-title":"-1 Receptor ligands. Potential in the treatment of neuropsychiatric disorders.","volume":"18","author":"Hayashi","year":"2004","journal-title":"CNS Drugs"},{"key":"R114-5-20210203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0169-328X(95)00283-X","article-title":"Regulation to dopamine D2 receptor affinity by cholecystokinin octapeptide in fibroblast cells contransfected with human CCKB and D21 receptor cDNAs.","volume":"36","author":"Dasgupta","year":"1996","journal-title":"Brain Res Mol Brain Res"},{"key":"R115-5-20210203","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0091-3057(97)00533-9","article-title":"Enhancement of latent inhibition in the rat by the CCK antagonist proglumide.","volume":"59","author":"Gracey","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"R116-5-20210203","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0196-9781(97)00187-3","article-title":"Pro-dopamine effects of neurotensin on sensorimotor gating deficits.","volume":"18","author":"Feifel","year":"1997","journal-title":"Peptides"},{"key":"R117-5-20210203","first-page":"1054","article-title":"Cerebrospinal fluid levels of neurotensin like immunoreactivity in normal controls and in patients with affective disorder, anorexia nervosa and premenstrual syndrome.","volume":"9","author":"Manberg","year":"1983","journal-title":"Soc Neurosci Abstr"},{"key":"R118-5-20210203","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/ajp.154.7.1019","article-title":"CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.","volume":"154","author":"Sharma","year":"1997","journal-title":"Am J Psychiatry"},{"key":"R119-5-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0149-7634(95)00016-X","article-title":"Antipsychotics and neuropeptides; the atypical profile of CI-943 and its relationship to neurotensin.","volume":"19","author":"Liegeois","year":"1995","journal-title":"Neurosci Biobehav Rev"},{"key":"R120-5-20210203","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatr"},{"key":"R121-5-20210203","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1176\/appi.ajp.162.3.633-b","article-title":"Neurotensin receptor agonists and antagonists for schizophrenia.","volume":"162","author":"Richelson","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R122-5-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00023210-200519040-00001","article-title":"Substance P receptor antagonists in psychiatry. Rationale for development and therapeutic potential.","volume":"19","author":"Herpfer","year":"2005","journal-title":"CNS Drugs"},{"key":"R123-5-20210203","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1345\/aph.18215","article-title":"Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists.","volume":"33","author":"Dixon","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"suppl 10","key":"R124-5-20210203","first-page":"22","article-title":"The biological basis of schizophrenia: new directions.","volume":"58","author":"Weinberger","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R125-5-20210203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0149-7634(05)80114-9","article-title":"Nitric oxide: a new messenger in the brain.","volume":"17","author":"Bruhwyler","year":"1993","journal-title":"Neurosci Biobehav Rev"},{"key":"R126-5-20210203","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1099-1077(199607)11:4<309::AID-HUP775>3.0.CO;2-B","article-title":"Affective disorders and nitric oxide: a role in pathways to relapse and refractoriness?","volume":"11","author":"Harvey","year":"1996","journal-title":"Hum Psychopharmacol"},{"key":"R127-5-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JCP.0b013e3181a6bc3b","article-title":"Synthetic -9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.","volume":"29","author":"Schwarcz","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R128-5-20210203","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.mp.4001029","article-title":"CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia.","volume":"7","author":"Ujike","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R129-5-20210203","first-page":"19","article-title":"Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia.","volume":"45","author":"Peet","year":"2008","journal-title":"Isr J Psychiatr Relat Sci"},{"key":"R130-5-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2710.2002.00410.x","article-title":"Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids.","volume":"27","author":"Citver","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"R131-5-20210203","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0920-9964(03)00068-9","article-title":"Secretin for refractory schizophrenia.","volume":"66","author":"Sheitman","year":"2004","journal-title":"Schizophr Res"},{"key":"R132-5-20210203","first-page":"66","article-title":"RG-1068 RepliGen.","volume":"4","author":"Wheeler","year":"2003","journal-title":"Curr Opin Invest Drugs"},{"key":"R133-5-20210203","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/archpsyc.65.8.955","article-title":"Estrogen in severe mental illness: a potential new treatment approach.","volume":"65","author":"Kulkarni","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"R134-5-20210203","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr Res"},{"key":"R135-5-20210203","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/sj.mp.4001907","article-title":"Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.","volume":"12","author":"Ehrenreich","year":"2007","journal-title":"Mol Psychiatry"},{"key":"R136-5-20210203","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0022-3565(25)23800-9","article-title":"Induction patterns of fos-like immunoreactivity in the forebrain as predictor of atypical antipsychotic activity.","volume":"271","author":"Robertson","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R137-5-20210203","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0165-6147(03)00232-3","article-title":"Dopamine receptor-interacting proteins: the Ca2+ connection in dopamine signaling.","volume":"24","author":"Bergson","year":"2003","journal-title":"Trends Pharmacol Sci"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201105000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:25:27Z","timestamp":1786044327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201105000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318215c2f7","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}